Aly‐Khan A. Lalani

Author

Aly‐Khan A. Lalani

Also Known As

A-K A Lalani, A-K. Lalani, A-K.A. Lalani, A. K. Lalani, A.-K. Lalani, A.K.A. Lalani, AK Lalani, Aly Khan A. Lalani, Aly-Khan A Lalani, Aly-Khan A. Lalani

180

Publications

2.7K

Citations

H-Index

Concepts

All Affiliations

Dana-Farber Cancer Institute Juravinski Cancer Centre McMaster University University of Ottawa University of Alberta

About

Aly‐Khan A. Lalani is an author at Dana-Farber Cancer Institute specializing in medicine, oncology, and urology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	15	446
2	Immunology	6	6	149
3	Health Sciences	4	4	61
4	Cell Biology	1	1	12
5	Cellular Therapies	1	1	12

Aly‐Khan A. Lalani

Publications

2.1K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Thomas Powles, Piotr Tomczak, Se Hoon Park, The Lancet Oncology	2022	262
Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma Aly‐Khan A. Lalani, Wanling Xie, Dylan J. Martini, Journal for ImmunoTherapy of Cancer	2018	256
Metabolomic adaptations and correlates of survival to immune checkpoint blockade Haoxin Li, Kevin Bullock, Carino Gurjao, Nature Communications	2019	217
The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma Rana R. McKay, Dominick Bossé, Wanling Xie, Cancer Immunology Research	2018	134
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study Robert J. Motzer, Camillo Porta, Masatoshi Eto, Journal of Clinical Oncology	2024	126
Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma Aly‐Khan A. Lalani, Wanling Xie, David A. Braun, European Urology Oncology UrologyAntibioticsAntibiotic UseMedicineAntibiotic Adjuvant	2019	94
Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma Bradley A. McGregor, Aly‐Khan A. Lalani, Wanling Xie, European Journal of Cancer OncologyGenitourinary CancerMedicineImmunologyImmune Checkpoint Inhibitor	2020	68
Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events Dylan J. Martini, Lana Hamieh, Rana R. McKay, Cancer Immunology Research	2018	61
Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma Matthew Scott Ernst, Vishal Navani, J. Connor Wells, European Urology	2023	58
Pan-urologic cancer genomic subtypes that transcend tissue of origin Fengju Chen, Yiqun Zhang, Dominick Bossé, Nature Communications	2017	57

Page 1